Alzamend Neuro Inc Dossier
Qualitative Analysis
Business overview
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's disease, bipolar disorder (BD), major depressive disorder (MDD), and post-traumatic stress disorder (PTSD). The company's pipeline consists of two primary therapeutic drug candidates: AL001, a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline, and salicylate; and ALZN002, a patented active immunotherapy approach using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine designed to restore the patient's immunological system to combat Alzheimer's by removing beta-amyloid from the brain.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the clinical development of AL001, a patented ionic cocrystal formulation of lithium combined with L-proline and salicylate. The initiative focuses on demonstrating superior brain penetration and a safer systemic profile compared to standard lithium carbonate across multiple indications.
Expected impact: Establish statistical significance across five studies (totaling 30 patients) to support a Section 505(b)(2) regulatory pathway, potentially eliminating the need for routine therapeutic drug monitoring (TDM).
Addressing Nasdaq Capital Market continued listing requirements. Following a deficiency notice regarding the $2.5 million minimum stockholders' equity requirement, the company is actively managing its capital structure.
Expected impact: Maintain public listing on the Nasdaq Capital Market to preserve access to public capital markets.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
MGH serves as the clinical trial site and contract research organization for the Phase II 'Lithium in Brain' clinical program. The collaboration leverages MGH's advanced imaging capabilities and clinical expertise, led by principal investigator Dr. Ovidiu Andronesi.
Terms: Terms of the contract research agreement are funded through Alzamend's ongoing capital raising activities.
Provides a flexible equity financing facility to sell shares of common stock from time to time, supporting working capital and clinical trial funding.
Terms: Allows for the issuance and sale of common stock up to an aggregate gross offering price of $3.0 million.